Alvotech (ALVOW)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Alvotech (ALVOW) trades at $0.26. Alvotech Holdings SA develops and manufactures biosimilars for global markets. The company is based in Iceland and aims to provide more affordable alternatives to branded biologic drugs. Market cap: $81.14M, Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for ALVOW: ALVOW does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ALVOW against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ALVOW: 1/1 perspectives are bearish.
Alvotech (ALVOW) Healthcare & Pipeline Overview
Alvotech Holdings SA is a biopharmaceutical company focused on developing and manufacturing biosimilars, offering cost-effective alternatives to branded biologic drugs. With a presence in global markets, Alvotech aims to improve patient access to essential medicines while navigating a competitive landscape and regulatory hurdles in the healthcare sector.
What Is the Investment Thesis for ALVOW?
Alvotech presents an investment opportunity within the growing biosimilars market, driven by the increasing demand for affordable biologic drugs. With a market capitalization of $0.10 billion and a P/E ratio of 16.49, Alvotech demonstrates potential for value creation. A gross margin of 55.4% indicates efficient operations. Catalysts include successful clinical trials and regulatory approvals for its biosimilar pipeline, expanding market access through strategic partnerships, and increasing adoption of biosimilars by healthcare providers and patients. Potential risks include competition from established pharmaceutical companies and other biosimilar manufacturers, regulatory hurdles and patent challenges, and the need for significant investment in research and development.
Based on FMP financials and quantitative analysis
ALVOW Key Highlights
- Market Cap of $0.10 billion reflects the company's current valuation in the market.
- P/E Ratio of 16.49 suggests the stock may be undervalued compared to its earnings.
- Profit Margin of 12.2% indicates the company's profitability after all expenses.
- Gross Margin of 55.4% demonstrates the efficiency of the company's production and pricing strategies.
- Beta of 0.18 suggests the stock is less volatile than the overall market.
Who Are ALVOW's Competitors?
Who Are ALVOW's Competitors?
ALVOW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BHC Bausch Health Companies Inc. | $5.75 | +0.35% | 3B | 50 |
| CHSYF China Medical System Holdings Limited | $1.35 | +0.00% | $3.27B | 53 |
| HMDCF HUTCHMED (China) Limited | $2.16 | +0.00% | $1.86B | — |
| ALVO Alvotech | $3.36 | +3.59% | $1.05B | 69 |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| MPXOF MPX International Corporation | $0.00 | +0.00% | 2K | 68 |
| AGRX Agile Therapeutics, Inc. | $1.51 | +3.42% | 11M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ALVOW's Key Strengths?
- Focus on biosimilars, a growing market segment.
- Strong research and development capabilities.
- Strategic partnerships with established pharmaceutical companies.
- Global presence and market access.
What Are ALVOW's Weaknesses?
- Limited product portfolio compared to larger pharmaceutical companies.
- Dependence on regulatory approvals for biosimilars.
- Competition from established players in the biosimilars market.
- Potential for patent challenges and litigation.
What Could Drive ALVOW Stock Higher?
- Clinical trial results for key biosimilar candidates.
- Regulatory approvals for biosimilars in major markets (e.g., US, Europe).
- Expansion of strategic partnerships with pharmaceutical companies.
- Increasing adoption of biosimilars by healthcare providers.
- Patent expiry of major biologic drugs, creating opportunities for biosimilar development.
What Are the Key Risks for ALVOW?
- Competition from established pharmaceutical companies and generic drug manufacturers.
- Regulatory hurdles and changing approval pathways for biosimilars.
- Pricing pressures and reimbursement challenges.
- Patent challenges and litigation related to biosimilars.
- Economic downturns and healthcare budget cuts impacting demand for biosimilars.
What Are the Growth Opportunities for ALVOW?
- Expanding Biosimilar Pipeline: Alvotech can expand its portfolio of biosimilars targeting various therapeutic areas, including autoimmune diseases, oncology, and inflammatory conditions. The global biosimilars market is projected to reach $35.7 billion by 2025, offering significant growth potential for Alvotech. Successful clinical trials and regulatory approvals for new biosimilars will drive revenue growth and market share gains.
- Strategic Partnerships: Alvotech can establish strategic partnerships with pharmaceutical companies and distributors to expand its market reach and commercialize its biosimilars in different regions. Collaborations with established players can provide access to distribution networks, marketing expertise, and regulatory support, accelerating market penetration and revenue growth. These partnerships can also reduce the financial burden of commercialization for Alvotech.
- Increasing Biosimilar Adoption: Alvotech can focus on increasing the adoption of biosimilars by healthcare providers and patients through education, awareness campaigns, and advocacy efforts. As healthcare systems prioritize cost-effective treatments, biosimilars are gaining acceptance as safe and effective alternatives to branded biologics. Alvotech can capitalize on this trend by demonstrating the value and benefits of its biosimilars to key stakeholders.
- Geographic Expansion: Alvotech can expand its operations into new geographic markets, particularly in emerging economies where there is a growing demand for affordable medicines. These markets offer significant growth opportunities for biosimilars due to increasing healthcare spending and a growing prevalence of chronic diseases. Alvotech can establish a presence in these markets through partnerships, acquisitions, or direct investment.
- Patent Expiry of Biologic Drugs: Alvotech can capitalize on the patent expiry of several blockbuster biologic drugs in the coming years, creating opportunities to develop and commercialize biosimilar versions. The market for biosimilars targeting these drugs is expected to be substantial, offering significant revenue potential for Alvotech. The company can accelerate its research and development efforts to bring these biosimilars to market quickly and capture market share.
What Opportunities Does ALVOW Have?
- Expanding biosimilar pipeline to target new therapeutic areas.
- Increasing biosimilar adoption by healthcare providers and patients.
- Geographic expansion into emerging markets.
- Patent expiry of blockbuster biologic drugs.
What Threats Does ALVOW Face?
- Competition from established pharmaceutical companies and generic drug manufacturers.
- Regulatory hurdles and changing approval pathways for biosimilars.
- Pricing pressures and reimbursement challenges.
- Economic downturns and healthcare budget cuts.
What Are ALVOW's Competitive Advantages?
- Intellectual property protection through patents and trade secrets.
- Regulatory expertise in obtaining approvals for biosimilars.
- Manufacturing capabilities and economies of scale.
- Strategic partnerships with established pharmaceutical companies.
What Does ALVOW Do?
Alvotech Holdings SA, based in Iceland, specializes in the development and manufacture of biosimilars. Founded with the mission of increasing patient access to affordable medicines, Alvotech focuses on creating biosimilar versions of established biologic drugs. These biosimilars offer similar efficacy and safety profiles to their branded counterparts but at a lower cost, potentially reducing healthcare expenses for patients and healthcare systems. The company's portfolio includes biosimilars targeting various therapeutic areas, including autoimmune diseases, oncology, and inflammatory conditions. Alvotech's strategy involves rigorous research and development, clinical trials, and regulatory approvals to ensure the quality and safety of its biosimilars. The company operates on a global scale, partnering with pharmaceutical companies and distributors to market its products in different regions. Alvotech's commitment to innovation and affordability positions it as a key player in the expanding biosimilars market, addressing the growing demand for cost-effective healthcare solutions. The company manages 1012 employees.
What Products and Services Does ALVOW Offer?
- Develop biosimilars of existing biologic drugs.
- Manufacture biosimilars for global markets.
- Conduct research and development to create new biosimilars.
- Perform clinical trials to ensure the safety and efficacy of biosimilars.
- Obtain regulatory approvals for biosimilars in various countries.
- Partner with pharmaceutical companies and distributors to market biosimilars.
How Does ALVOW Make Money?
- Develop and manufacture biosimilars at a lower cost than branded biologics.
- Sell biosimilars to pharmaceutical companies and distributors.
- Generate revenue through licensing agreements and royalties.
- Focus on high-value biosimilars with significant market potential.
What Industry Does ALVOW Operate In?
Alvotech operates within the specialty and generic drug manufacturing industry, a segment experiencing growth due to increasing healthcare costs and patent expirations of branded drugs. The biosimilars market is expanding as healthcare systems seek cost-effective alternatives to expensive biologic medications. The competitive landscape includes established pharmaceutical companies, generic drug manufacturers, and other biosimilar developers. Alvotech aims to capture market share by offering high-quality biosimilars at competitive prices, leveraging its research and development capabilities and strategic partnerships.
Who Are ALVOW's Key Customers?
- Pharmaceutical companies
- Drug distributors
- Healthcare providers
- Patients
ALVOW Financials
ALVOW Latest News
No recent news available for ALVOW.
ALVOW Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ALVOW.
Price Targets
Wall Street price target analysis for ALVOW.
ALVOW MoonshotScore
What does this score mean?
The MoonshotScore rates ALVOW's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Vilhelm Robert Wessman
CEO
Vilhelm Robert Wessman is the CEO of Alvotech, bringing extensive experience in the pharmaceutical industry. His career includes leadership roles in various healthcare companies, where he focused on strategic development, operational efficiency, and market expansion. Wessman's background encompasses a deep understanding of the global pharmaceutical landscape, regulatory affairs, and biosimilar development. He is known for his strategic vision and ability to drive growth in competitive markets. He is responsible for managing 1012 employees.
Track Record: Under Vilhelm Robert Wessman's leadership, Alvotech has focused on expanding its biosimilar pipeline and securing regulatory approvals in key markets. Wessman has overseen strategic partnerships to enhance market access and commercialization efforts. Key milestones include advancing clinical trials for multiple biosimilar candidates and strengthening the company's position in the global biosimilars market.
Alvotech Healthcare Stock: Key Questions Answered
What does Alvotech do?
Alvotech Holdings SA develops and manufactures biosimilars, which are near-identical copies of original biologic drugs. These biosimilars offer a more affordable alternative to expensive branded biologics, addressing the growing demand for cost-effective healthcare solutions. Alvotech's business model revolves around researching, developing, and commercializing biosimilars across various therapeutic areas, including autoimmune diseases, oncology, and inflammatory conditions. The company aims to improve patient access to essential medicines while navigating a competitive landscape and regulatory hurdles in the pharmaceutical industry.
What do analysts say about ALVOW stock?
Analyst consensus on Alvotech (ALVOW) is currently pending. Key valuation metrics to consider include the company's market capitalization of $0.10 billion and its P/E ratio of 16.49. Growth considerations involve the successful development and commercialization of its biosimilar pipeline, expansion into new geographic markets, and increasing adoption of biosimilars by healthcare providers. Investors should monitor regulatory approvals, clinical trial results, and competitive dynamics in the biosimilars market to assess Alvotech's growth potential.
What are the main risks for ALVOW?
Alvotech faces several risks, including competition from established pharmaceutical companies and generic drug manufacturers in the biosimilars market. Regulatory hurdles and changing approval pathways for biosimilars can delay or impede product launches. Pricing pressures and reimbursement challenges may impact profitability. Patent challenges and litigation related to biosimilars pose legal and financial risks. Economic downturns and healthcare budget cuts could reduce demand for biosimilars. These factors could affect Alvotech's financial performance and market position.
What are the key factors to evaluate for ALVOW?
Evaluating ALVOW involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Focus on biosimilars, a growing market segment. Primary risk to monitor: Competition from established pharmaceutical companies and generic drug manufacturers. This is not financial advice.
How frequently does ALVOW data refresh on this page?
ALVOW prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ALVOW's recent stock price performance?
Recent price movement in Alvotech (ALVOW) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on biosimilars, a growing market segment. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ALVOW overvalued or undervalued right now?
Determining whether Alvotech (ALVOW) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ALVOW?
Before investing in Alvotech (ALVOW), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- AI analysis pending for ALVOW, limiting comprehensive insights.
- Financial data based on available information as of 2026-03-17.